Why the study?
Does apolipoprotein A-I (apoA-I)/HDL raising reduce atherosclerosis more effectively in early-stage versus late-stage disease?
Does apolipoprotein A-I (apoA-I)/HDL raising reduce atherosclerosis more effectively in early-stage versus late-stage disease?
The timing of HDL raising is critical, with greater atheroprotective effects in early-stage versus late-stage atherosclerosis, which may explain neutral results in clinical trials of patients with advanced disease.
Answers are grounded in this paper and cite their sources.
May warrant earlier HDL intervention; leaves open timing-specific trials in early atherosclerosis.
Preclinical studies have shown benefit of apolipoprotein A-I (apoA-I)/high-density lipoprotein (HDL) raising in atherosclerosis; however, this has not yet translated into a successful clinical therapy. Our studies demonstrate that apoA-I raising is more effective at reducing early-stage atherosclerosis than late-stage disease, indicating that the timing of HDL raising is a critical factor in its atheroprotective effects. To date, HDL-raising clinical trials have only been performed in aged patients with advanced atherosclerotic disease. Our findings therefore provide insight, related to important temporal aspects of HDL raising, as to why the clinical trials have thus far been largely neutral.
No takes yet. Share an insight, caveat, or question.
Morton et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: